Table 1. The Cytotoxic Effects of Umbelliprenin Against Colon, Breast, and Glioma Cancer Cell Lines, Human and Mouse Bone Marrow-Derived Stem Cells (BMDSCs), and Peripheral Blood Mononuclear Cells (PBMCs)a.
| Cell line | 24 hours | 48 hours | 72 hours |
|---|---|---|---|
| HT29 | 36.4 ± 1.6 (33.4 to39.8) | 33.6 ± 3.1 (28.1 to 40.1) | 37.1 ± 1.4 (34.5 to 39.8) |
| CT26 | 51.4 ± 2.9 (46 to 57.4) | 53.2 ± 3.6 (46.6 to 60.8) | 56.37 ± 2.5 (51.6 to 61.6) |
| MCF-7 | 40.8 ± 3.8 (34 to 49) | 36.04 ± 1.6 (33.1 to 39.2) | 55.8 ± 4.5 (47.8 to 65.2) |
| 4T1 | 30.9 ± 3.1 (25.5 to 37.6) | 30.6 ± 2.6 (26 to 36.2) | 62.2 ± 4.8 (53.6 to 72.2) |
| A172 | 51.9 ± 6.7 (40.5 to 66.5) | 37.9 ± 2.1 (33.9 to 42.3) | 43.6 ± 4.3 (36 to 52.9) |
| GL26 | 50.2 ± 4.6 (42 to 60) | 46.1 ± 2.9 (40.8 to 52.1) | 51.5 ± 1.3 (46.4 to 57.1) |
| Human BMDSCS | 254.7 ± 21 (216.8 to 299.1) | 193 ± 8.4 (177.2 to 210.2) | 120.4 ± 5 (111.1 to 130.6) |
| Mouse BMDSCS | 204.4 ± 4.5 (195.8 to 213.4) | 180.2 ± 7 (167 to 194.5) | 159 ± 7.3 (145.4 to 173.9) |
| Human PBMCs | 713.5 ± 499.1 (232.6 to 2189) | 1269 ± 1198.6 (320.7 to 5019) | 3657 ± 3748.9 (90.44 to 14786.1) |
| Mouse PBMCs | 6651 ± 3670.7 (2603 to 16992) | 3273 ± 1879.3 (1244 to 8611) | 714.1 ± 143.2 (486.6 to 1048) |
aThe inhibition concentrations of 50% (IC50 values) were measured by MTT assay following 24, 48, and 72 hours of treatment with umbelliprenin. Data is expressed as mean ± SEM, and the parentheses indicate a 95% confidence interval on the mean.